title: High dose intravenous immunoglobulin treatment: mechanisms of action.
abstract: Intravenous immunoglobulin (IVIg) treatment was introduced as replacement therapy for patients with antibody deficiencies, but evidence suggests that a wide range of immune-mediated conditions could benefit from IVIg. The immunoglobulins are precipitated from human plasma by fractionation methods. In conclusion, the differences in basic fractionation methods and the addition of various modifications for purification, stabilization, and virus inactivation result in products significantly different from each other.
authors.affiliation: Recanati/Miller Transplantation Institute, The Mount Sinai School of Medicine, PO Box 1504, New York, NY 10029-6574, USA. peter.boros@msnyuhealth.org
authors.forename: Peter
authors.initials: P
authors.lastname: Boros
authors.forename: Gabriel
authors.initials: G
authors.lastname: Gondolesi
authors.forename: Jonathan S
authors.initials: JS
authors.lastname: Bromberg
mesh_terms: D004305:Dose-Response Relationship, Drug; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007109:Immunity / Q000187:drug effects / Q000502:physiology*; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage* / Q000627:therapeutic use; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D016377:Organ Transplantation; D016896:Treatment Outcome
chemical_list: D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors